Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | UBE2M | P61081 | 3/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.46 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179254 | 0.93 | HIF1A (0.56) | HIF1AEPAS1KDM4EPOLBSRPK1 | |
| SCHEMBL1443280 | 0.91 | DRD2 (0.51) | HIF1AEPAS1KDM4EMAPTALDH1A1 | |
| SCHEMBL1442923 | 0.90 | DRD2 (0.44) | HIF1AEPAS1KDM4EMEN1MAPT | |
| SCHEMBL13276228 | 0.90 | HIF1A (0.57) | HIF1AEPAS1KDM4EPOLBUBE2M | |
| SCHEMBL1442810 | 0.89 | HTR1A (0.51) | HIF1AEPAS1KDM4EPOLBMEN1 | |
| SCHEMBL10178967 | 0.89 | KCNQ2 (0.46) | HIF1AEPAS1MEN1MAPTKMT2A | |
| SCHEMBL12812469 | 0.89 | HTR1A (0.44) | HIF1AEPAS1MAPTHTR1ADRD2 | |
| SCHEMBL27865644 | 0.89 | HTR1A (0.44) | HIF1AEPAS1KDM4EMAPTALDH1A1 | |
| SCHEMBL12812052 | 0.89 | PSEN1 (0.51) | KDM4EMAPTKMT2AALDH1A1HSD17B10 | |
| SCHEMBL1442424 | 0.88 | DRD2 (0.47) | HIF1AEPAS1HTR1ADRD2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | claimed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | claimed |
| CN-102596932-A | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER SCHERING PHARMA AG | 2012-07-18 | — | — | CN | claimed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340528-B2 | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-18 | — | — | US | disclosed |
| WO-2011026579-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263708-A1 | SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS | ABL1, TYK2, JAK2 | HIF1A 2989/4885EPAS1 1421/4885KDM4E 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.